Literature DB >> 7878687

Binding kinetics of fluticasone propionate to the human glucocorticoid receptor.

P Högger1, P Rohdewald.   

Abstract

Receptor-ligand interactions of fluticasone propionate (FP), a glucocorticoid used for inhalation therapy, were determined and compared with dexamethasone, budesonide, and beclomethasone-17-monopropionate, the active metabolite of beclomethasone dipropionate. Two approaches, evaluation of binding kinetics and competition assays, were applied to obtain relative receptor affinities (RRAs) with dexamethasone as reference. A higher association rate constant and a distinctly lower dissociation rate constant for FP compared with the other glucocorticoids resulted in an equilibrium dissociation constant (Kd) of 0.49 nmol/l. Kd dexamethasone was 9.36 nmol/l; derived RRA of FP was 1910. The calculated half-time of the FP-receptor complex was 10 h, thus exceeding the half-times of all other glucocorticoids as well as their RRAs. Competition assays clearly confirmed the rank order of the tested glucocorticoids, although RRAs were generally lower than those found in kinetic assays and strongly dependent on the assay conditions. The high receptor affinity of FP is reflected by clinical trials demonstrating its superiority to other glucocorticoids. For therapeutic application, the long half-time of the FP-receptor complex should support the practicality of longer dose-intervals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7878687     DOI: 10.1016/0039-128x(94)90054-x

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  17 in total

1.  Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma.

Authors:  R J Meijer; H A Kerstjens; L R Arends; H F Kauffman; G H Koëter; D S Postma
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Glucocorticoid hormone-induced chromatin remodeling enhances human hematopoietic stem cell homing and engraftment.

Authors:  Bin Guo; Xinxin Huang; Scott Cooper; Hal E Broxmeyer
Journal:  Nat Med       Date:  2017-03-06       Impact factor: 53.440

3.  Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.

Authors:  D J Clark; B J Lipworth
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

4.  Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.

Authors:  B J Lipworth; D J Clark; L C McFarlane
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

5.  Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies.

Authors:  Jie Shao; James Talton; Yaning Wang; Lawrence Winner; Guenther Hochhaus
Journal:  AAPS J       Date:  2020-01-30       Impact factor: 4.009

6.  Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.

Authors:  D J Clark; A Grove; R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

7.  Systemic effects of glucocorticoids--a response.

Authors:  R W Fuller; A Bye; N S Baber
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

8.  Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children.

Authors:  D J Clark; R A Clark; B J Lipworth
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

Review 9.  Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.

Authors:  P Saberi; T Phengrasamy; D P Nguyen
Journal:  HIV Med       Date:  2013-04-16       Impact factor: 3.180

10.  Assessment of HPA-Axis Suppression with Fluticasone Cream 0.05% in Patients with Extensive Psoriasis or Eczema.

Authors:  E H Tschen; A D Bucko
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.